Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

Abstract

Although several randomized clinical trials and observational studies have evaluated the effectiveness, safety and drug survival of etanercept (ETN) in the treatment of psoriatic arthritis (PsA), long-term data regarding these aspects are currently scarce. For this reason, we sought to investigate the long-term survival and safety of ETN in PsA patients in 4 tertiary care Spanish hospitals over a 13-year observation period (from 2004 to 2017). The records of 85 PsA patients were reviewed. ETN showed an excellent survival profile, with rates of treatment discontinuation at 1, 3, 5 and 10 years of 15, 37, 46 and 59%, respectively. In our cohort, a trend toward longer drug survival in patients with shorter disease duration and those who were treated with ETN as their first biologic agent was observed. On the other hand, combination therapy with conventional disease-modifying antirheumatic drugs did not provide greater improvement on the long-term drug survival. Only 12% of the patients reported adverse events (AEs) during therapy, being most of them of mild to moderate intensity, and in only 7% AEs led to drug discontinuation. To the best of our knowledge, the present study shows the largest follow-up period of ETN-treated population analyzed in a real-life setting, and these results demonstrate the positive safety profile and long-term effectiveness of this biologic agent in the management of PsA patients.

Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

“…Our study addresses a notable discrepancy in the literature concerning sex differences in response to TNFi treatment. Whereas previous studies have shown contrasting results 18–23 or have identified sex differences only in unadjusted analyses, 24–27 our findings align with those studies indicating that women have a reduced probability of responding to TNFi treatment compared to men 34–39 . The real‐world data used in this study encompass a highly diverse patient population, representative of a significant portion of Europe, which strengthens the generalizability and applicability of our findings to clinical practice.…”

“…Although accumulating evidence indicates that female sex is associated with reduced TNFi effectiveness, [10][11][12][13][14][15][16][17] some studies either present conflicting results [18][19][20][21][22][23] or reveal sex differences only in unadjusted analyses. [24][25][26][27] Given these contrasting findings, there's a need for more extensive and robust research to characterize sex differences in response to treatment.…”

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis

“…Compared to SEC, multiple patient registries and observational cohort studies have examined the survival of different anti-TNFs in biologic-experienced (mainly anti-TNFs) patients. In these studies, the 1 year drug survival ranged widely from 51 to 77% (12,(20)(21)(22)(23)(24)(25)(26)(27). Nevertheless, real life data comparing directly anti-TNF and anti-IL17 (SEC) drug survival are missing.…”